Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET

[1]  Young Hee Jung,et al.  The Cortical Neuroanatomy Related to Specific Neuropsychological Deficits in Alzheimer's Continuum , 2019, Dementia and neurocognitive disorders.

[2]  D. Y. Lee,et al.  Clinical and Biomarker Characteristics According to Clinical Spectrum of Alzheimer’s Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD , 2019, Journal of clinical medicine.

[3]  Y. Hong,et al.  Prediction of Alzheimer's Pathological Changes in Subjective Cognitive Decline Using the Self-report Questionnaire and Neuroimaging Biomarkers , 2019, Dementia and neurocognitive disorders.

[4]  C. DeCarli,et al.  Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using 18F-AV1451 Positron Emission Tomography Imaging , 2018, JAMA neurology.

[5]  Si Eun Kim,et al.  Amyloid involvement in subcortical regions predicts cognitive decline , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Keith A. Johnson,et al.  PET staging of amyloidosis using striatum , 2018, Alzheimer's & Dementia.

[7]  J. Sepulcre,et al.  In vivo staging of regional amyloid deposition , 2017, Neurology.

[8]  J. Seibyl,et al.  Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid , 2017, Psychiatry Research: Neuroimaging.

[9]  Hanna Cho,et al.  In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum , 2016, Annals of neurology.

[10]  L. Flicker,et al.  18 F PET ligands for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) , 2016 .

[11]  Lennart Thurfjell,et al.  Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.

[12]  M. Mintun,et al.  Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid , 2013, Annals of neurology.

[13]  N. Foster,et al.  Amyloid deposition and cognition in older adults: the effects of premorbid intellect. , 2013, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[14]  J. Trojanowski,et al.  Inter-laboratory variation when using a unified test procedure for INNO-BIA AlzBio3 , 2013, Alzheimer's & Dementia.

[15]  J. Trojanowski,et al.  Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers. , 2013, Clinical chemistry.

[16]  T. Yen,et al.  Regional Amyloid Deposition in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Evaluated by [18F]AV-45 Positron Emission Tomography in Chinese Population , 2013, PloS one.

[17]  James Robert Brašić,et al.  Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography. , 2012, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[18]  Elizabeth C Mormino,et al.  Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. , 2012, Archives of neurology.

[19]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[20]  John Seibyl,et al.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.

[21]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[22]  Robert A. Dean,et al.  Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI , 2011, Acta Neuropathologica.

[23]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[24]  Sang Won Seo,et al.  Seoul Neuropsychological Screening Battery-Dementia Version (SNSB-D): A Useful Tool for Assessing and Monitoring Cognitive Impairments in Dementia Patients , 2010, Journal of Korean medical science.

[25]  D. Segal.  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) , 2010 .

[26]  Cindee M. Madison,et al.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.

[27]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[28]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[29]  Anders Wallin,et al.  Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. , 2005, Clinical chemistry.

[30]  B. Lee,et al.  Interchanging Scores Between Clinical Dementia Rating Scale and Global Deterioration Scale , 2003, Alzheimer disease and associated disorders.

[31]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[32]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[33]  G. Frisoni,et al.  Modifiable Risk Factors for Prevention of Dementia in Midlife, Late Life and the Oldest-Old: Validation of the LIBRA Index. , 2017, Journal of Alzheimer's disease : JAD.

[34]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[35]  D. Y. Lee,et al.  Development of the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K)Clinical and Neuropsychological Assessment Batteries , 2002 .